Literature DB >> 18620016

Co-morbidities associated with influenza-attributed mortality, 1994-2000, Canada.

Dena L Schanzer1, Joanne M Langley, Theresa W S Tam.   

Abstract

The elderly and persons with specific chronic conditions are known to face elevated morbidity and mortality risks resulting from an influenza infection, and hence are routinely recommended for annual influenza vaccination. However, risk-specific mortality rates have not been established. We estimated age-specific influenza-attributable mortality rates stratified by the presence of chronic conditions and type of residence based on deaths of persons who were admitted to hospital with a respiratory complication captured in our national database. The majority of patients had chronic heart or respiratory conditions (80%) and were admitted from the community (80%). Influenza-attributable mortality rates clearly increase with age for all risk groups. Our influenza-specific estimates identified higher risk ratios for chronic lung or heart disease than have been suggested by other methods. These estimates identify groups most in need of improved vaccines and for whom the use of additional strategies, such as immunization of household contacts or caregivers should be considered.

Entities:  

Mesh:

Year:  2008        PMID: 18620016     DOI: 10.1016/j.vaccine.2008.06.087

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

1.  Influenza and seasonal patterns of hospital use by older adults in long-term care and community settings in Ontario, Canada.

Authors:  Andrea Gruneir; Jeff C Kwong; Michael A Campitelli; Alice Newman; Geoffrey M Anderson; Paula A Rochon; Vincent Mor
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

2.  Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis.

Authors:  Lidia Brydak; Julie Roiz; Pascaline Faivre; Camille Reygrobellet
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

3.  Employer-incurred health care costs and productivity losses associated with influenza.

Authors:  Sudeep Karve; Derek A Misurski; Genevieve Meier; Keith L Davis
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

4.  Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study.

Authors:  Darren Lau; Dean T Eurich; Sumit R Majumdar; Alan Katz; Jeffrey A Johnson
Journal:  Diabetologia       Date:  2014-02-06       Impact factor: 10.122

5.  Prevalence of seasonal influenza vaccination and associated factors in people with chronic diseases in Hong Kong.

Authors:  H Y Tsui; J T F Lau; C Lin; K C Choi
Journal:  Epidemiol Infect       Date:  2012-04-23       Impact factor: 4.434

6.  Statistical estimates of absenteeism attributable to seasonal and pandemic influenza from the Canadian Labour Force Survey.

Authors:  Dena L Schanzer; Hui Zheng; Jason Gilmore
Journal:  BMC Infect Dis       Date:  2011-04-12       Impact factor: 3.090

7.  The geographic synchrony of seasonal influenza: a waves across Canada and the United States.

Authors:  Dena L Schanzer; Joanne M Langley; Trevor Dummer; Samina Aziz
Journal:  PLoS One       Date:  2011-06-28       Impact factor: 3.240

8.  Threat-responsiveness and the decision to obtain free influenza vaccinations among the older adults in Taiwan.

Authors:  Ying-Chun Li; Chi-Mei Liu
Journal:  BMC Public Health       Date:  2009-07-31       Impact factor: 3.295

9.  Estimating sensitivity of laboratory testing for influenza in Canada through modelling.

Authors:  Dena L Schanzer; Michael J Garner; Todd F Hatchette; Joanne M Langley; Samina Aziz; Theresa W S Tam
Journal:  PLoS One       Date:  2009-08-18       Impact factor: 3.240

Review 10.  Antibody-Based Strategies to Prevent and Treat Influenza.

Authors:  Zachary Shriver; Jose M Trevejo; Ram Sasisekharan
Journal:  Front Immunol       Date:  2015-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.